Skip to main content

Table 3 The diagnostic criteria of VEGF tested and in combination analysis with HE4 and CA125 in ovarian cancer patients

From: The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors

Epithelial ovarian cancer Diagnostic criteria (%) VEGF HE4 CA125 VEGF + HE4 VEGF + CA125 HE4+ CA125 VEGF + HE4 + CA125
I stage Sensitivity 44 44 40 76 72 72 84
Specificity 94 94 92 88 88 88 82
PV-PR 78 78 71 76 75 75 70
  PV-NR 77 77 75 88 86 86 91
II stage Sensitivity 48 28 64 64 76 80 96
Specificity 94 94 92 88 88 88 82
PV-PR 75 70 80 72 76 76 72
  PV-NR 74 72 83 83 88 89 97
III stage Sensitivity 72 68 80 88 92 88 96
Specificity 94 94 92 88 88 88 82
PV-PR 85 85 83 78 79 78 72
  PV-NR 87 85 90 93 95 93 97
IV stage Sensitivity 40 80 84 88 92 92 96
Specificity 94 94 92 88 88 88 82
PV-PR 76 86 84 78 79 95 72
  PV-NR 75 85 92 93 95 79 97
Total group Sensitivity 48 55 67 81 83 83 93
Specificity 94 94 92 88 88 88 82
PV-PR 94 94 94 93 93 93 91
  PV-NR 47 51 58 69 72 72 85
Serous epithelial Sensitivity 46 70 64 81 77 88 94
Specificity 94 94 92 88 88 88 82
PV-PR 89 88 92 88 87 88 95
  PV-NR 71 74 71 81 78 88 93
Endometrioid epithelial Sensitivity 50 36 69 71 91 80 95
Specificity 94 94 92 88 88 88 82
PV-PR 88 80 91 84 87 86 83
  PV-NR 67 61 77 77 93 83 95